Core Viewpoint - The company has received temporary approval from the FDA for its abbreviated new drug application (ANDA) for Sitagliptin Metformin Extended-Release Tablets, indicating progress in its product development and potential market entry in the U.S. [1] Company Summary - The company's subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., submitted the ANDA for Sitagliptin Metformin Extended-Release Tablets to the FDA [1] - The drug is primarily used for treating type 2 diabetes patients who have inadequate blood sugar control with Metformin alone or are receiving combination therapy [1] - The original drug, Janumet XR, was developed by Merck and launched in the U.S. in February 2012, and it is currently under patent protection [1] Market Potential - The U.S. market sales for Sitagliptin Metformin Extended-Release Tablets are projected to be approximately $1.1 billion in 2024 [1] - The company has invested around RMB 14.73 million in the research and development of this product to date [1] Competitive Position - The FDA's approval signifies that the company's product has met safety and efficacy standards comparable to the original drug, enhancing its market competitiveness [1] - The product will only be eligible for sale in the U.S. market after the patent expires and the FDA grants final approval [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., has received temporary approval from the FDA for its Abbreviated New Drug Application (ANDA) for Sitagliptin Metformin Extended-Release Tablets, which are used for treating type 2 diabetes patients whose blood sugar is not adequately controlled with metformin alone or who are receiving combination therapy [1] Group 1 - The Sitagliptin Metformin Extended-Release Tablets are primarily indicated for type 2 diabetes patients [1] - The original drug, JanumetXR, was developed by Merck and launched in the U.S. in February 2012 [1] - Currently, the original product is the only one available in the U.S. market, as it is still under patent protection [1] Group 2 - The projected sales for the drug in the U.S. market in 2024 are approximately $1.1 billion [1]

Core Viewpoint - Jiuzhou Pharmaceutical's subsidiary, Jiuzhou Biotech, has received temporary approval from the FDA for the ANDA of Sitagliptin Metformin Extended-Release Tablets, which is primarily used for blood sugar control in type 2 diabetes patients [1] Group 1 - The drug is a generic version of Janumet XR, originally developed by Merck [1] - The total R&D investment by Jiuzhou Pharmaceutical in this drug amounts to approximately 14.73 million yuan [1] - The approval of the ANDA will enhance the company's market competitiveness, although the product must wait for patent expiration and final FDA approval to be eligible for sale in the U.S. market [1]

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Tofisopam, an oral anticoagulant drug, which will enhance the company's product portfolio and market competitiveness [1][1][1] Summary by Relevant Sections Product Approval - The company has obtained the "Chemical Raw Material Drug Marketing Application Approval Notice" for Tofisopam, indicating compliance with national drug registration requirements [1][1] - The drug is primarily used for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as for treating or preventing deep vein thrombosis and pulmonary embolism [1][1] Market Potential - In 2023, the sales revenue of Tofisopam in domestic sample hospitals and retail pharmacies was approximately 361 million yuan [1][1] - The company submitted the marketing application to the Center for Drug Evaluation in July 2024 and has invested about 6.69 million yuan in the research and development of Tofisopam to date [1][1] Strategic Impact - The approval of Tofisopam is expected to enrich the company's product structure and enhance its market competitiveness [1][1]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Tofacitinib, indicating a significant milestone for the company in expanding its product portfolio [2] Group 1 - The company announced the receipt of the approval notice for Tofacitinib, with the notification number 2025YS01026 [2]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Tofisopam Tosylate, an oral anticoagulant drug aimed at preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as treating or preventing deep vein thrombosis and pulmonary embolism [1] Company Summary - The company submitted the marketing application for Tofisopam Tosylate to the National Medical Products Administration in July 2024 and has recently obtained the approval notification [1] - Cumulative research and development investment in Tofisopam Tosylate has reached approximately RMB 6.69 million [1] Industry Summary - The main manufacturers of Tofisopam Tosylate in China include Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1] - Sales of Tofisopam Tosylate tablets in domestic sample hospitals and urban pharmacies amounted to approximately RMB 361 million in 2023 [1]

Core Viewpoint - The approval of tolvaptan sulfate by the National Medical Products Administration enhances the company's product portfolio and competitiveness, although it is expected to have no significant short-term impact on performance due to uncertainties in drug production and sales [1] Summary by Categories Regulatory Approval - The company has received the approval notice for the listing application of tolvaptan sulfate from the National Medical Products Administration [1] - The drug is an oral anticoagulant, with the listing application submitted in July 2024 [1] Research and Development Investment - The company has invested approximately 6.69 million yuan in the research and development of this active pharmaceutical ingredient [1] Market Performance - In 2023, the sales revenue of tolvaptan sulfate tablets in domestic sample hospitals and urban pharmacies was approximately 361 million yuan [1] - The approval is expected to enrich the company's product structure and enhance competitiveness [1]

证券代码：603456 证券简称：九洲药业 公告编号：2025-068 浙江九洲药业股份有限公司 关于公司收到化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江九洲药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）颁发的关于甲苯磺酸艾多沙班的《化学原料 药上市申请批准通知书》（通知书编号：2025YS01026），具体情况如下： 一、药品的基本情况 药品名称：甲苯磺酸艾多沙班 注册标准编号：YBY71722025 包装规格：1kg/桶，2kg/桶，5kg/桶，10kg/桶，15kg/桶，20kg/桶，25kg/桶 申请事项：境内生产化学原料药上市申请 生产企业：浙江九洲药业股份有限公司，浙江省台州市椒江区外沙路工业区 （外沙路 99 号） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品其他相关情况 甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防 ...